Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26552
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWeinberg, Laurence-
dc.contributor.authorLi, Michael Hua-Gen-
dc.contributor.authorChurilov, Leonid-
dc.contributor.authorMacgregor, Christopher-
dc.contributor.authorGarrett, Kent-
dc.contributor.authorEyles, Jade-
dc.contributor.authorBellomo, Rinaldo-
dc.date2021-05-19-
dc.date.accessioned2021-05-24T05:45:00Z-
dc.date.available2021-05-24T05:45:00Z-
dc.date.issued2021-05-19-
dc.identifier.citationPloS One 2021; 16(5): e0251718en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26552-
dc.description.abstractSaline and Plasma-Lyte have different physiochemical contents; consequently, they may differently affect patients' renal function. We compared the effects of fluid therapy with 0.9% saline and with Plasma-Lyte 148 on renal function as assessed by creatinine concentration among patients undergoing major surgery. We conducted a prospective, double-blinded cluster crossover trial comparing the effects of the two fluids on major surgery patients. The primary aim was to establish the pilot feasibility, safety and preliminary efficacy evidence base for a large interventional trial to establish whether saline or Plasma-Lyte is the preferred crystalloid fluid for managing major surgery patients. The primary efficacy outcome was the proportion of patients with changes in renal function as assessed by creatinine concentration during their index hospital admission. We used changes in creatinine to define acute kidney injury (AKI) according to the RIFLE criteria. The study was feasible with 100% patient and clinician acceptance. There were no deviations from the trial protocol. After screening, we allocated 602 patients to saline and 458 to Plasma-Lyte. The median (IQR) volume of intraoperative fluid received was 2000 mL (1000:2000) in both groups. Forty-nine saline patients (8.1%) and 49 Plasma-Lyte patients (10.7%) developed a postoperative AKI (adjusted incidence rate ratio [aIRR]: 1.34; 95% CI: 0.93-1.95; p = 0.120). No differences were observed in the development of postoperative complications (aIRR: 0.98; 95% CI: 0.89-1.08) or the severity of the worst complication (aIRR: 1.00; 95% CI: 0.78-1.30). The median (IQR) length of hospital stay was six days (3:11) for the saline group and five days (3:10) for the Plasma-Lyte group (aIRR: 0.85; 95% CI: 0.73-0.98). There were no serious adverse events relating to the trial fluids, nor were there fluid crossover or contamination events. The study design was feasible to support a future follow-up larger clinical trial. Patients treated with saline did not demonstrate an increased incidence of postoperative AKI (defined as changes in creatinine) compared to those treated with Plasma-Lyte. Our findings imply that clinicians can reasonably use either solution intraoperatively for adult patients undergoing major surgery. Registry: Australian New Zealand Clinical Trials Registry; ACTRN12613001042730; URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364988.en
dc.language.isoeng
dc.titleThe effects of 0.9% saline versus Plasma-Lyte 148 on renal function as assessed by creatinine concentration in patients undergoing major surgery: A single-centre double-blinded cluster crossover trial.en
dc.typeJournal Articleen
dc.identifier.journaltitlePloS Oneen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationIntensive Careen
dc.identifier.affiliationAnaesthesiaen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationPharmacyen
dc.identifier.affiliationMelbourne Brain Centre at Royal Melbourne Hospital, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1371/journal.pone.0251718en
dc.type.contentTexten
dc.identifier.orcid0000-0001-7403-7680en
dc.identifier.orcid0000-0003-4305-399Xen
dc.identifier.pubmedid34010324
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.